DDX19A: A Potential Drug Target and Biomarker for RNA Helicase-Driven Therapies

Target Name: DDX19A

NCBI ID: G55308

DDX19A

DDX19A: A Potential Drug Target and Biomarker for RNA Helicase-Driven Therapies

Abstract:

DDX19A (ATP-dependent RNA helicase DDX19A (isoform 1)) is a protein that plays a critical role in the regulation of RNA stability and dynamics. It is a potential drug target and biomarker for RNA-based therapeutics. This article summarizes the current understanding of DDX19A, its functions, and potential therapeutic applications.

Introduction:

RNA-based therapeutics have shown promising results in treating various diseases, including cancer, neurodegenerative diseases, and inherited disorders. However, the development of these therapies has been hindered by the limited understanding of the molecular mechanisms underlying RNA stability and dynamics. The discovery of DDX19A, an ATP-dependent RNA helicase, has provided new insights into the regulation of RNA stability and dynamics and has implications for the development of RNA-based therapeutics.

Current Understanding of DDX19A:

DDX19A is a 28-kDa protein that belongs to the ATP-dependent RNA helicase family 1 (ADH1). It is expressed in various tissues and cells and is involved in the regulation of RNA stability and dynamics. DDX19A functions as a helicase, which means it can unwinds double-stranded RNA molecules and forms single-stranded domains. This process is ATP-dependent and allows DDX19A to efficiently process RNA in a cell-specific manner.

Function and Interactions:

DDX19A is involved in the regulation of various cellular processes, including gene expression, translation, and RNA stability. It has been shown to play a role in the regulation of stem cell self-renewal and differentiation. DDX19A has also been shown to be involved in the regulation of cancer cell growth and survival.

In addition to its role in cellular processes, DDX19A is also a potential drug target. Its ATP-dependent nature and involvement in the regulation of RNA stability make it an attractive target for small molecules and other therapeutic agents.

Potential Therapeutic Applications:

The discovery of DDX19A has implications for the development of RNA-based therapeutics. By targeting DDX19A, researchers could develop new drugs that improve the stability and dynamics of RNA and enhance the efficacy of RNA-based therapies.

One potential application of DDX19A as a drug target is in the treatment of neurodegenerative diseases. neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the buildup of toxic hallucinations. Many of these diseases are caused by the buildup of abnormally aggregated RNA, including misfolded proteins and short snippets of RNA. By targeting DDX19A, researchers could develop new treatments that reduce the production of toxic RNA and improve the stability and dynamics of RNA in the brain.

Another potential application of DDX19A as a drug target is in the treatment of cancer. cancer cells have the ability to generate new copies of themselves and can also produce a large amount of RNA as part of their normal growth and survival processes. The production of excess RNA is a common feature of cancer cells, and it can contribute to the development and progression of cancer. By targeting DDX19A, researchers could develop new treatments that reduce the production of excess RNA and inhibit the growth of cancer cells.

Conclusion:

In conclusion, DDX19A is a protein that plays a critical role in the regulation of RNA stability and dynamics. Its ATP-dependent nature and involvement in the regulation of cellular processes make it an attractive target for small molecules and other therapeutic agents. The discovery of DDX19A has implications for the development of RNA-based therapeutics, particularly for the treatment of neurodegenerative diseases and cancer. Further research is needed to fully understand the functions of DDX19A and its potential as a drug target.

1. ADH1:

2.

Protein Name: DEAD-box Helicase 19A

Functions: ATP-dependent RNA helicase involved in mRNA export from the nucleus. Rather than unwinding RNA duplexes, DDX19 functions as a remodeler of ribonucleoprotein particles, whereby proteins bound to nuclear mRNA are dissociated and replaced by cytoplasmic mRNA binding proteins

The "DDX19A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX19A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets